肠源性氧化三甲胺对缺血性心力衰竭大鼠预后的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (3443 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of trimethylamine oxide (TMAO) on the prognosis of ischemic heart failure rats. Methods SD rats were randomly divided into normal control group, sham group, model group (HF) and intervention group (HF-DMB). Rats in HF and HF-DMB groups underwent myocardial infarction simulation via ligation, and cardiac function was assessed at 4 weeks (4 W), 8 weeks (8 W) and 12 weeks (12 W) after surgery, respectively . The levels of Serum TMAO, BNP, CRP, LPS and IL-6 were detected, along with histological examination of myocardial tissue using HE and Masson staining. Fecal samples were also collected for 16S rDNA high-throughput sequencing analysis. Results Compared with Control group, HF group exhibited a significant decline in (LVEF) over time, the difference was most pronounced in the eighth week(27.68±6.41)%,also with a notable increase in circulating TMAO [(9534.02±202.75)nmol/L, (12713.06±243. 66)nmol/L, (4970.95±168.15) nmol/L], BNP[(37.26±3.41)ng/L, (59.17±3.80)ng/L, (58.83±4.41)ng/L], CRP[(179.30±13.85) μg/L, (186.40±13.47) μg/L, (187.21±11.35) μg/L], LPS[(92. 45±8.83)ng/L, (90.65±7.5) ng/L, (95.20±4.68) ng/L], IL-6[(97.57±3.48) pg/ml, (102.60±4.96) pg/ml, (107.70±4.70) pg/ml], levels compared with the control group (P<0.05). Myocardial pathological staining showed that more myocardial cells survived and the degree of fibrosis was reduced in HF-DMB group than in HF group. Sequencing analysis revealed increased microbial richness in the HF-DMB group compared with the HF group with increased Firmicutes and decreased Bacteroidetes at 8 weeks, resulting in a lowered Firmicutes/Bacteroidetes ratio. However, these changes were reversed in the HF-DMB-8W group. Conclusions Changes of circulating TMAO in ischemic heart failure rats are consistent with traditional heart failure evaluation markers. Specific inhibition of circulating TMAO can improve various indexes of heart failure, indicating its potential clinical value in heart failure treatment and prognostic assessment.

Key words： trimethylamine oxide heart failure 3,3-dimethyl-1-butanol gut microbiota

Received: 29 January 2024

ZTFLH:

R364.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xin
	SHI Rui
	NI Jianmei
	LIU Xiaowei
	GUO Qiong
	WANG Tao
	WANG Xiaojing
	CHEN Shaobo

Cite this article:

ZHANG Xin,SHI Rui,NI Jianmei等. Effect of intestinal-derived trimethylamine oxide levels on prognosis of ischemic heart failure rats[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 474-479.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I6/474

[1]	Chioncel O, Mebazaa A, Harjola V P, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC heart failure long-term registry[J].Eur J Heart Fail, 2017, 19(10):1242-1254.
[2]	Tang W H W, Backhed F, Landmesser U, et al. Intestinal microbiota in cardiovascular health and disease: Jacc state-of-the-art review[J].J Am Coll Cardiol,2019,73(16):2089-2105.
[3]	Tang W H, Kitai T, Hazen S L. Gut microbiota in cardiovascular health and disease[J].Circ Res, 2017, 120(7): 1183- 1196.
[4]	Mei Z, Chen G C, Wang Z, et al. Dietary factors, gut microbiota, and serum trimethylamine-n-oxide associated with cardiovascular disease in the hispanic community health study/study of latinos[J].Am J Clin Nutr, 2021, 113 (6): 1503- 1514.
[5]	Ahmad A F, Caparros-Martin J A, Gray N, et al. Insights into the associations between the gut microbiome, its metabolites, and heart failure[J].Am J Physiol Heart Circ Physiol, 2023, 325 (6): H1325-H1336.
[6]	Ivashkin V T, Kashukh Y A.Impact of l-carnitine and phosphatidylcholine containing products on the proatherogenic metabolite tmao production and gut microbiome changes in patients with coronary artery disease[J].Vopr Pitan, 2019, 88 (4): 25-33.
[7]	Ge X, Zheng L, Zhuang R, et al. The gut microbial metabolite trimethylamine n-oxide and hypertension risk: A systematic review and dose-response meta-analysis[J].Adv Nutr, 2020, 11(1): 66-76.
[8]	Tang W H, Wang Z, Li X S, et al. Increased trimethylamine n-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus[J].Clin Chem, 2017, 63(1): 297-306.
[9]	Senthong V, Wang Z, Fan Y, et al. Trimethylamine n-oxide and mortality risk in patients with peripheral artery disease [J].J Am Heart Assoc,2016,5(10):e004237
[10]	Tan Y, Sheng Z, Zhou P, et al. Plasma trimethylamine n-oxide as a novel biomarker for plaque rupture in patients with st-segment-elevation myocardial infarction[J].Circ Cardiovasc Interv, 2019, 12(1):e007281.
[11]	Luciani M, Muller D, Vanetta C, et al. Trimethylamine-n-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation[J].Heart,2023,109(5):396-404.
[12]	Tang W H, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-n-oxide in patients with heart failure: refining the gut hypothesis[J].J Am Coll Cardiol, 2014, 64 (18): 1908-1914.
[13]	Li Z, Wu Z, Yan J, et al. Gut microbe-derived metabolite trimethylamine n-oxide induces cardiac hypertrophy and fibrosis[J].Lab Invest,2019,99(3):346-357.
[14]	Sun X, Jiao X, Ma Y, et al. Trimethylamine n-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ros-txnip-nlrp3 inflammasome[J].Biochem Biophys Res Commun, 2016, 481(1-2): 63-70.
[15]	Makrecka-Kuka M, Volska K, Antone U, et al. Trimethylamine n-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria[J].Toxicol Lett,2017,267(32-38).
[16]	Takala J. Determinants of splanchnic blood flow[J].Br J Anaesth,1996,77(1):50-58.
[17]	Tang W H W, Li D Y and Hazen S L. Dietary metabolism, the gut microbiome, and heart failure[J].Nat Rev Cardiol, 2019, 16(3):137-154.
[18]	Liu L, Kaur G I, Kumar A, et al. The role of gut microbiota and associated compounds in cardiovascular health and its therapeutic implications[J].Cardiovasc Hematol Agents Med Chem,2024, Online ahead of print.
[19]	Huc T, Drapala A, Gawrys M, et al. Chronic, low-dose tmao treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats[J].Am J Physiol Heart Circ Physiol,2018,315(6):H1805-H1820.
[20]	Collins H L, Drazul-Schrader D, Sulpizio A C, et al. L-carnitine intake and high trimethylamine n-oxide plasma levels correlate with low aortic lesions in apoe(-/-) transgenic mice expressing cetp[J].Atherosclerosis,2016,244(29-37).
[21]	Yin J, Liao S X, He Y, et al. Dysbiosis of gut microbiota with reduced trimethylamine-n-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack[J].J Am Heart Assoc,2015,4(11):1-10.